Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aerovate Therapeutics Inc (NQ: AVTE )

16.16 +0.45 (+2.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 105,053
Open 15.85
Bid (Size) 12.36 (1)
Ask (Size) 25.48 (2)
Prev. Close 15.71
Today's Range 15.36 - 16.45
52wk Range 9.410 - 30.79
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Recap: Aerovate Therapeutics Q3 Earnings
Via Benzinga

Performance

YTD
-40.21%
-40.21%
1 Month
+45.78%
+45.78%
3 Month
+6.39%
+6.39%
6 Month
-4.38%
-4.38%
1 Year
-11.74%
-11.74%

More News

Read More
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Recap: Aerovate Therapeutics Q1 Earnings
Via Benzinga
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
Via Benzinga
10 Short Squeeze Candidates: Getty Images, Genius Brands, MicroStrategy And More
Via Benzinga
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Ambrx Biopharma, PaxMedica And 3 More Short Squeeze Stocks That Could Soar This Week
Via Benzinga
Singing Machine, Blue Apron, Camber Energy And More Short Squeeze Candidates That Could Soar This Week
Via Benzinga
Singing Machine, SurgePays And 3 More Short Squeeze Stocks That Could Soar This Week
Via Benzinga
JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Dow Jumps 600 Points; US Inflation Rate Slows In November
Via Benzinga
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Bitcoin Holder MicroStrategy, SurgePays And 3 Other Short Squeeze Stocks That Could Soar This Week
Via Benzinga
Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis
Via Benzinga
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.